ARCH Venture Partners IX, LLC - 12 Aug 2022 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
10%+ Owner
Signature
By: ARCH Venture Partners IX, LLC, By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Issuer symbol
VIR
Transactions as of
12 Aug 2022
Net transactions value
$0
Form type
4
Filing time
16 Aug 2022, 21:04:59 UTC
Previous filing
10 Jun 2022
Next filing
22 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Other $0 -217,781 -2.8% $0.000000 7,586,037 12 Aug 2022 See footnote F1, F2
transaction VIR Common Stock Other $0 -282,219 -2.8% $0.000000 9,830,626 12 Aug 2022 See footnote F1, F3
transaction VIR Common Stock Other $0 +13,076 +9.2% $0.000000 155,286 12 Aug 2022 Direct F1, F4, F5
transaction VIR Common Stock Other $0 +1,475 +9.3% $0.000000 17,283 12 Aug 2022 Direct F1, F4, F6
transaction VIR Common Stock Other $0 +2,952 +9.3% $0.000000 34,586 12 Aug 2022 See footnote F1, F4, F7
transaction VIR Common Stock Other $0 -217,781 -2.9% $0.000000 7,368,256 15 Aug 2022 See footnote F1, F2
transaction VIR Common Stock Other $0 -282,219 -2.9% $0.000000 9,548,407 15 Aug 2022 See footnote F1, F3
transaction VIR Common Stock Other $0 +13,076 +8.4% $0.000000 168,362 15 Aug 2022 Direct F1, F4, F5
transaction VIR Common Stock Other $0 +1,475 +8.5% $0.000000 18,758 15 Aug 2022 Direct F1, F4, F6
transaction VIR Common Stock Other $0 +2,952 +8.5% $0.000000 37,538 15 Aug 2022 See footnote F1, F4, F7
transaction VIR Common Stock Other $0 -217,781 -3% $0.000000 7,150,475 16 Aug 2022 See footnote F1, F2
transaction VIR Common Stock Other $0 -282,219 -3% $0.000000 9,266,188 16 Aug 2022 See footnote F1, F3
transaction VIR Common Stock Other $0 +13,076 +7.8% $0.000000 181,438 16 Aug 2022 Direct F1, F4, F5
transaction VIR Common Stock Other $0 +1,475 +7.9% $0.000000 20,233 16 Aug 2022 Direct F1, F4, F6
transaction VIR Common Stock Other $0 +2,952 +7.9% $0.000000 40,490 16 Aug 2022 See footnote F1, F4, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Distribution of Common Stock held by a limited partnership to its partners for no consideration.
F2 These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
F3 These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
F4 Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.
F5 Shares held directly by Crandell.
F6 Shares held directly by Bybee.
F7 Shares held by a trust for the benefit of family members of Bybee.